Pluri (NASDAQ:PLUR – Get Free Report) and REGENXBIO (NASDAQ:RGNX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Analyst Recommendations
This is a summary of recent ratings and price targets for Pluri and REGENXBIO, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
| REGENXBIO | 1 | 3 | 9 | 1 | 2.71 |
REGENXBIO has a consensus target price of $23.17, suggesting a potential upside of 246.81%. Given REGENXBIO’s stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Pluri.
Profitability
This table compares Pluri and REGENXBIO’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pluri | -2,344.59% | N/A | -82.71% |
| REGENXBIO | -112.58% | -220.07% | -46.04% |
Valuation and Earnings
This table compares Pluri and REGENXBIO”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pluri | $1.02 million | 12.24 | -$23.82 million | ($2.45) | -0.40 |
| REGENXBIO | $174.48 million | 2.53 | -$193.88 million | ($3.79) | -1.76 |
Pluri has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Pluri has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
Insider & Institutional Ownership
16.6% of Pluri shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
REGENXBIO beats Pluri on 9 of the 15 factors compared between the two stocks.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
About REGENXBIO
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
